The Rise and Fall of Amarin
Not all that long ago, biotech company Amarin was a Stocktwits user’s dream. The company increased by more than 500% in two weeks, from Sept. 21 to Oct. 5, 2018, after Amarin’s promising new drug trial showed that it was “effective in benefiting cardiovascular patients.”
The target market was a broad one — there’s no shortage of people with cholesterol problems and early stage heart disease. The drug’s results were unprecedented: Vascepa was shown to reduce risk of an adverse cardiovascular event by 25%. 💡